CAC 40
8 088,24 +71,59 (+0,89 %) Euro Stoxx 50
5 006,85 +67,84 (+1,37 %) Dow Jones
38 239,66 +153,86 (+0,40 %) EUR/USD
1,0699 -0,0034 (-0,32 %) Gold future
2 349,60 +7,10 (+0,30 %) Bitcoin EUR
59 722,13 -767,09 (-1,27 %)
Bristol-Myers Squibb Company (BMY)
Échanges après Bourse :
Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543
United States
609 252 4621
https://www.bms.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 34 100
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Christopher S. Boerner Ph.D. | CEO & Chairman | 3,14M | S.O. | 1971 |
| Mr. David V. Elkins | Executive VP & CFO | 2,28M | S.O. | 1968 |
| Ms. Sandra Leung Esq. | Executive VP & General Counsel | 2,58M | S.O. | 1961 |
| Mr. Samit Hirawat M.D. | Executive VP, Chief Medical Officer & Head of Development | 2,62M | S.O. | 1969 |
| Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer | S.O. | S.O. | 1973 |
| Mr. Timothy Power | VP & Head of Investor Relations | S.O. | S.O. | S.O. |
| Ms. Kimberly M. Jablonski | Chief Compliance & Ethics Officer | S.O. | S.O. | S.O. |
| Ms. Ahn Amanda Poole | Executive Vice President & Chief Human Resources Officer | S.O. | S.O. | 1975 |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs | S.O. | S.O. | 1949 |
| Mr. Adam Lenkowsky | Executive VP, Chief Commercialization Officer & Head of U.S. Oncology | S.O. | S.O. | 1972 |
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Bristol-Myers Squibb Company en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 5; Société : 6; Droits des actionnaires : 2; Compensation : 1.
